Life science investment company Ally Bridge Group said on Thursday that it has supported and led an over-subscribed USD65m financing of Pulmonx Corporation.
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx Corporation is a provider of diagnostic and therapeutic pulmonary device technologies, with its key product approved and marketed in the US, Europe, Australia, and Asia, including China.
Pulmonx's key product, Zephyr Valve, is the first minimally-invasive device approved by the US FDA for treating patients with severe emphysema, a progressive and life-threatening form of COPD. The Zephyr Valve treatment is included in emphysema treatment guidelines issued by leading health organisations worldwide, including the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the UK's National Institute for Health and Care Excellence (NICE), Ally Bridge Group said.
The company's investment in Pulmonx follows new or follow-on investments in Axonics (NASDAQ:AXNX), Vapotherm (NASDAQ:VAPO), OrthoPediatrics (NASDAQ:KIDS), Shockwave Medical (NASDAQ:SWAV) and Silk Road Medical (NASDAQ:SILK).
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib